Introducing our new blood-stage malaria vaccine immunogen based on the essential invasion protein PfCyRPA. By understanding where on PfCyRPA the best antibodies bind, we used structure guided design to generate PfCyRPA-EM, which contains only the epitopes of the best antibodies.
